On September 2, 2026, a clinical trial update was recorded for the study titled "Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients," registered as NCT06284590. This is a Phase 2 study, and its current status is listed as recruiting.
The trial is evaluating intratumoral administration of L19IL2, L19TNF, or a combination of L19IL2 and L19TNF, given alongside pembrolizumab, in patients with unresectable melanoma. No results have been posted for this study as part of this update, and no efficacy or safety outcomes are described at this stage.
This entry reflects the trial's recruitment status only, based on the record dated September 2, 2026. Corticotropin, an approved compound, is referenced in connection with this update, though the specific role of corticotropin within this trial protocol is not detailed in the available event data.
Readers interested in learning more about corticotropin, including its approved uses and background, can consult the compound overview for additional context.